Even individuals whose symptoms do not yet meet the criteria for clinical depression benefit from therapeutic interventions. This conclusion comes from a new meta-study by researchers who analyzed ...
LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...